Are Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Mixed Financials Driving The Negative Sentiment?
With its stock down 12% over the past month, it is easy to disregard Haisco Pharmaceutical Group (SZSE:002653). It seems that the market might have completely ignored the positive aspects of the com
Pulling Back 5.5% This Week, Haisco Pharmaceutical Group's SZSE:002653) Five-year Decline in Earnings May Be Coming Into Investors Focus
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. To wit, the Haisco Pharmaceutical Group share pric
What Kind Of Shareholders Hold The Majority In Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Shares?
The big shareholder groups in Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) have power over the company. Institutions often own shares in more established companies, while it's not unusual to s
Haisco Pharmaceutical Group (SZSE:002653) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Haisco Pharmaceutical Group (SZSE:002653) Posted Weak Earnings But There Is More To Worry About
The market shrugged off Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) weak earnings report. Despite the market responding positively, we think that there are several concerning factors that
Hesco: the application for non-public offering of shares is approved by the Securities and Futures Commission
Hesco (002653) announced that the company recently received a "reply on approving the non-public offering of shares of Haiscox Pharmaceutical Group Co., Ltd." issued by the China Securities Regulatory Commission, approving the non-public offering of no more than 40 million new shares.
Hesco: 163000 shares held by Wang Junmin, the controlling shareholder and one of the actual controllers, account for 0.02% of the company's total share capital.
Hesco (002653) announced that the company recently received notice from Wang Junmin, the controlling shareholder and one of the actual controllers, that 163000 shares held by Wang Junmin had been pledged, accounting for 0.02% of the company's total share capital.
Hesco's latest announcement: clinical trial application for HSK36273 for injection accepted
Hesco announced that it has obtained the "acceptance notice" of the application for HSK36273 clinical trials for innovative drugs. HSK36273 for injection is an intravenous anticoagulant EP7041 introduced by the company. Hisco has its exclusive license in mainland China for clinical use in hemodialysis and systemic anticoagulation in patients during surgery. The chairman of the company is Wang Junmin. Wang Junmin, male, born in 1968, Chinese nationality, permanent residence in Singapore, graduated from Cheung Kong Business School, master's degree. Mr. Wang Junmin used to be the sales manager of the pharmaceutical factory of West China Medical University, and served as a doctor of Hayes from 2007 to March 2019.
Hesco (002653.SZ): Wang Junmin, the controlling shareholder, pledged 3.17 million shares, extended the pledge period 9.1 million shares, and pledged 13 million shares.
002653.SZ announced that the company has recently received notice from Wang Junmin, the company's controlling shareholder and actual controller, that some of Wang Junmin's shares held by Wang Junmin have been pledged, extended and cancelled, with 3.17 million shares pledged, 9.1 million shares extended and 13 million shares pledged.
Wang Junmin, the real controller of 002653.SZ, pledged 3.17 million shares and 13 million shares.
Zhitong Financial APP News, 002653.SZ issued an announcement that the company recently received notice from Mr. Wang Junmin, the controlling shareholder and actual controller of the company, that part of the shares held by Mr. Wang Junmin had been pledged, extended and released. Mr. Wang Junmin pledged 3.17 million shares, accounting for 0.30% of the total share capital of the company, and released 13 million shares, accounting for 1.21% of the total share capital of the company.